A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

In a report released today, Emily Field from Barclays maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

CORE EARNINGS PER SHARE: Core earnings per share are expected to rise to $2.07 from $1.45 the year prior, according to the same consensus. AstraZeneca's stock is up 7.9% since the start of 2024.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A revival in AstraZeneca Plc shares faces a key test ... firm’s cancer drugs and data privacy breaches. Since then, the stock has risen more than 15%, outperforming European pharmaceutical ...

AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million government offer, citing ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

In a report released today, James Gordon from J.P. Morgan maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.

If an investor was to purchase shares of AZN stock at the current price level of $70.69/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...